Literature DB >> 24783252

Clinical factors associated with accuracy of EUS-FNA for pancreatic or peripancreatic solid mass without on-site cytopathologists.

Jaihwan Kim, Ji Kon Ryu, Jin Myung Park, Woo Hyun Paik, Byeong Jun Song, Yong-Tae Kim, Yong Bum Yoon.   

Abstract

BACKGROUND AND AIMS: Endoscopic ultrasound-guided fine needle aspiration (EUSFNA) is a safe and effective technique for tissue diagnosis in patients with pancreatic or peripancreatic solid masses. However, the procedure is difficult to accomplish without an on-site cytopathologist. The aims of this study were to examine the outcomes of EUS-FNA for pancreatic or peripancreatic solid masses without an on-site cytopathologist and to determine the factors associated with diagnostic accuracy.
METHODS: From December 2005 to November 2011, 230 patients with pancreatic or peripancreatic solid masses had 240 EUS-FNAs performed without an on-site cytopathologist. The medical records of the 230 patients from a single tertiary center were retrospectively reviewed.
RESULTS: Among the 230 patients who underwent EUS-FNA, 201 patients (88%) had malignancy, which included 171 adenocarcinomas (74%). Assuming that the cytopathological malignancy was positive or suspicious for malignant cells with cytology, the accuracy without an on-site cytopathologist was 67.9%. However, the accuracy increased from 40.0% for the first 30 cases (from 2006 to 2008) to 83.3% for the last 30 cases (in 2011) and was constantly over 80.0% starting from the sixth octile onwards for every 30 cases (in 2011). From the analysis of factors associated with the accuracy of the diagnosis using logistic regression analysis, the number of needle passes and the experience of endosonographer were statistically associated with the diagnostic accuracy.
CONCLUSIONS: In the case of performing EUS-FNA for pancreatic or peripancreatic solid masses without an on-site cytopathologist, the experience of the endosonographer, and the number of needle passes were associated with the diagnostic accuracy.

Entities:  

Mesh:

Year:  2014        PMID: 24783252     DOI: 10.1111/jgh.12497

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

2.  Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer.

Authors:  Shunsuke Watanabe; Jun Miyoshi; Masao Toki; Komei Kambayashi; Shuichi Kitada; Takeshi Nosaka; Tomoyuki Goto; Hirotaka Ota; Kazushige Ochiai; Koichi Gondo; Nobuhito Ikeuchi; Shujiro Tsuji; Kenji Nakamura; Junji Shibahara; Tadakazu Hisamatsu
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

Review 3.  Endoscopic ultrasonography-guided tissue acquisition for small solid pancreatic lesions: Does the size matter?

Authors:  Yousuke Nakai; Tsuyoshi Hamada; Ryunosuke Hakuta; Kazunaga Ishigaki; Kei Saito; Tomotaka Saito; Naminatsu Takahara; Suguru Mizuno; Hirofumi Kogure; Kazuhiko Koike; Mitsuhiro Fujishiro
Journal:  DEN open       Date:  2021-09-28

4.  Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.

Authors:  Manoj K Bhasin; Kenneth Ndebele; Octavian Bucur; Eric U Yee; Hasan H Otu; Jessica Plati; Andrea Bullock; Xuesong Gu; Eduardo Castan; Peng Zhang; Robert Najarian; Maria S Muraru; Rebecca Miksad; Roya Khosravi-Far; Towia A Libermann
Journal:  Oncotarget       Date:  2016-04-26

5.  A Multicenter comparative trial of a novel EUS-guided core biopsy needle (SharkCore) with the 22-gauge needle in patients with solid pancreatic mass lesions.

Authors:  Mariam Naveed; Ali A Siddiqui; Thomas E Kowalski; David E Loren; Ammara Khalid; Ayesha Soomro; Syed M Mazhar; Joseph Yoo; Raza Hasan; Silpa Yalamanchili; Nicholas Tarangelo; Linda J Taylor; Douglas G Adler
Journal:  Endosc Ultrasound       Date:  2018 Jan-Feb       Impact factor: 5.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.